Abstract
Background: Galectin-9 (Gal-9) is a member of the galectin family of lectins that exhibit binding affinity for β-galactosides. We found a T cell line-derived Gal-9 with novel eosinophil chemoattractant activity, but its role in eosinophilic inflammation of the lung is unknown. We evaluated the role of Gal-9 in Ascaris suum-induced eosinophilic lung inflammation in mice. Methods: To evaluate the role of Gal-9 in Ascaris suum-induced eosinophilic lung inflammation, we developed a mouse model of eosinophilic pneumonia induced by the Ascaris suum antigen, and analyzed eosinophilic inflammation in Gal-9-deficient mice. The therapeutic effects of recombinant Gal-9 on lung inflammation were also examined in this mouse model. To evaluate lung inflammation, numbers of inflammatory cells and cytokine levels in the bronchoalveolar lavage fluid (BALF) were estimated by flow cytometry and enzyme-linked immunosorbent assay, respectively. Results: The BALF of this mouse model of eosinophilic pneumonia induced by the Ascaris suum antigen contained increased numbers of inflammatory cells and elevated Gal-9 levels. Compared with wild-type mice, the BALF of Gal-9-deficient mice contained higher numbers of both eosinophils and T helper type 2 (Th2) cells. Th2 cytokines and eotaxin levels were also higher, and levels of CD4+CD25+Foxp3+ regulatory T cells were lower in Gal-9-deficient mice than in wild-type mice. Intranasal administration of recombinant Gal-9 prevented eosinophilic inflammation of the lung and upregulated the release of endogenous Gal-9. Conclusions: Our findings suggest that Gal-9 negatively regulates Th2-mediated eosinophilic inflammation of the lung and that Foxp3+ regulatory T cells might be involved in suppressing allergic inflammation.
Journal Section:
Original Paper
References
1.
Leffler H: Introduction to galectins. Trends Glycosci Glycobiotech 1997;9:9–19.
2.
Hirashima M, Kashio Y, Nishi N, Yamauchi A, Imaizumi T, Kageshita T, Saita N, Nakamura T: Galectin-9 in physiological and pathological conditions. Glycoconj J 2004;19:593–600.
[PubMed]
3.
Kashio Y, Nakamura K, Abedin MJ, Seki M, Nishi N, Yoshida N, Nakamura T, Hirashima M: Galectin-9 induces apoptosis through the calcium-calpain-caspase-1 pathway. J Immunol 2003;170:3631–3636.
[PubMed]
4.
Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury S, Zheng XX, Strom T B, Kuchroo V K: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005;6:1245–1252.
[PubMed]
5.
Yamamoto H, Kashio Y, Shoji H, Shinonaga R, Yoshimura T, Nishi N, Nabe T, Nakamura T, Kohno S, Hirashima M: Involvement of galectin-9 in guinea pig allergic airway inflammation. Int Arch Allergy Immunol 2007;143(suppl 1):95–105.
[PubMed]
6.
Katoh S, Nobumoto A, Matsumoto N, Matsumoto K, Ehara N, Niki T, Inada H, Nishi N, Yamauchi A, Fukushima K, Hirashima M: Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia. Int Arch Allergy Immunol 2010;153:294–302.
[PubMed]
7.
Tsuboi Y, Abe H, Nakagawa R, Oomizu S, Watanabe K, Nishi N, Nakamura T, Yamauchi A, Hirashima M: Galectin-9 protects mice from the Shwartzman reaction by attracting prostaglandin E2-producing polymorphonuclear leukocytes. Clin Immunol 2007;124:221–233.
8.
Matsumoto N, Katoh S, Mukae H, Matsuo T, Takatsu, K, Matsukura S: Critical role of IL-5 antigen-induced pulmonary eosinophilia, but not in lymphocyte activation. Int Arch Allergy Immunol 2003;130:209–215.
[PubMed]
9.
Nishi N, Itoh A, Fujiyama A, Yoshida N, Araya S-I, Hirashima M, Shoji H, Nakamura T: Development of highly stable galectins: truncation of the linker peptide confers protease-resistance on tandem-repeat type galectins. FEBS Lett 2005;579:2058–2064.
[PubMed]
10.
Katoh S, Matsumoto N, Kawakita K, Tominaga A, Kincade PW, Matsukura S: A role for CD44 in an antigen-induced murine model of pulmonary eosinophilia. J Clin Invest 2003;111:1563–1570.
[PubMed]
11.
Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos J-C, Levinson D, Radbruch A, Kamradt T: T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;95:6930–6935.
[PubMed]
12.
Monney L, Sabatos CA, Gaglia JL, Ryu A, Waldner H, Chernova T, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002;415:536–541.
[PubMed]
13.
Miyazaki E, Nureki S, Fukami T, Shigenaga T, Ando M, Ito K, Ando H, Sugisaki K, Kumamoto T, Tsuda T: Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia. Am J Respir Crit Care Med 2002;165:1125–1131.
[PubMed]
14.
Katoh S, Fukushima K, Matsumoto N, Matsumoto K, Abe K, Onai N, Matsushima K, Matsukura S. Accumulation of CCR4-expressing CD4+ T cells and high concentration of its ligands (TARC and MDC) in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. Allergy 2003;58:1–6.
15.
Matsumoto R, Matsumoto H, Seki M, Hata M, Asano Y, Kanegasaki S, Stevens RL, Hirashima M: Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 1998;273:16976–16984.
[PubMed]
16.
Saita N, Goto E, Yamamoto T, Cho I, Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, Nakamura K, Hirashima M: Association of galectin-9 with eosinophil apoptosis. Int Arch Allergy Immunol 2002;128:42–50.
[PubMed]
17.
Rabinovich AG, Liu F-T, Hirashima M: An emerging role for galectins in tuning the immune response: Lessons from experimental models of inflammatory disease, autoimmunity and cancer. Scand J Immunol 2007;66:143–158.
[PubMed]
18.
Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S, Kojima K, Nagahara K, Miyake M, Yamauchi A, Kohrogi H, Hirashima M: Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur J Immunol 2010;40:548–558.
19.
Kojima K, Arikawa T, Saita N, Goto E, Tsumura S, Tanaka R, Masunaga A, Niki T, Oomizu S, Hirashima M, Kohrogi H: Galectin-9 atenuates acute lung injury by expanding CD14––plasmacytoid dendritic cell-like macrophages. Am J Respir Crit Care Med 2010;184:328–339.
20.
Katoh S, Ishii N, Nobumoto A, Takeshita K, Dai S-Y, Shinonaga R, Niki T, Nishi N, Tominaga A, Yamauchi A, Hirashima M: Galectin-9 inhibits CD44-hyaluronan interaction and suppresses a murine model of allergic asthma. Am J Respir Crit Care Med 2007;176:27–35.
[PubMed]
21.
Shevach EM: CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2:389–400.
[PubMed]
22.
Wood KJ, Sakaguchi S: Regulatory lymphocytes: regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003;3:199–210.
[PubMed]
23.
Maloy KJ, Powrie F: Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2:816–822.
[PubMed]
24.
O’Garra A, Vieira P: Regulatory T cells and mechanisms of immune system control. Nat Med 2004;10:801–805.
[PubMed]
25.
Paust S, Cantor H: Regulatory T cells and autoimmune disease. Immunol Rev 2005;204:195–207.
26.
Sakaguchi S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000;101:455–458.
[PubMed]
27.
Shevach EM: Regulatory T cells in autoimmunity. Annu Rev Immunol 2000;18:423–449.
[PubMed]
28.
Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911–920.
[PubMed]
29.
Sheikh A, Smeeth L, Hubbard R: There is no evidence of an inverse relationship between TH2-mediated atopy and TH1-mediated autoimmune disorders: lack of support for the hygiene hypothesis. J Allergy Clin Immunol 2003;111:131–135.
30.
De Lafaille MAC, Lafaille JJ: CD4+ regulatory T cells in autoimmunity and allergy. Curr Opin Immunol 2002;14:771–778.
31.
Gambineri E, Torgerson TR, Ochs HD: Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance, a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 2003;15:430–435.
[PubMed]
32.
Kearley J, Barker JE, Robinson DS, Lloyd CM: Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent. J Exp Med 2005;202:1539–1547.
[PubMed]
33.
Wing K, Sakaguchi S: Regulatory T cells as potential immunotherapy in allergy. Curr Opin Allergy Clin Immunol 2006;6:482–488.
[PubMed]
34.
Hawrylowicz CM, O’Garra A: Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat Rev Immunol 2005;5:271–283.
[PubMed]
35.
Seki M, Oomizu S, Sakata K, Sakata A, Arikawa T, Ito K, Takeshita K, Niki T, Saita N, Nishi N, Yamauchi A, Katoh S, Matsukawa A, Kuchroo VK, Hirashima M: Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol 2008;127:78–88.
[PubMed]
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
